Efficacy and safety of diacerein in patients with inadequately controlled type 2 diabetes: A randomized controlled trial

Diabetes Care

Volumn 40, Issue 10, 2017, Pages 1356-1363

  Cardoso, Claudia R L ^a   Leite, Nathalie C ^a   Carlos, Fernanda O ^a   Loureiro, Andréia ^a   Viegas, Bianca B ^a   Salles, Gil F ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; DIACEREIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; PLACEBO; SULFONYLUREA DERIVATIVE; ANTHRAQUINONE DERIVATIVE; ANTIINFLAMMATORY AGENT; GLYCOSYLATED HEMOGLOBIN;

ADD ON THERAPY; ADULT; AGE; AGED; ARTICLE; CLINICAL OUTCOME; CLINICAL PROTOCOL; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC PATIENT; DIARRHEA; DISEASE DURATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN CELL; HYPERTENSION; HYPOGLYCEMIA; LOOSE FECES; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SEX; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; BIOASSAY; BODY MASS; DOSE RESPONSE; EXERCISE; FOLLOW UP; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME; WAIST CIRCUMFERENCE;

AGED; ANTHRAQUINONES; ANTI-INFLAMMATORY AGENTS; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; EXERCISE; FEMALE; FOLLOW-UP STUDIES; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; TREATMENT OUTCOME; WAIST CIRCUMFERENCE;

EID: 85035798811     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc17-0374     Document Type: Article

References (35)

1. Donath MY. Targeting inflammation in the treatment of type 2 diabetes: Time to start. Nat Rev Drug Discov 2014;13:465-476
2. Herder C, Dalmas E, Böni-Schnetzler M, Donath MY. The IL-1 pathway in type 2 diabetes and cardiovascular complications. Trends Endocrinol Metab 2015;26:551-563
3. Maiorino MI, Bellastella G, Giugliano D, Esposito K. Cooling down inflammation in type 2 diabetes: How strong is the evidence for cardiometabolic benefit? Endocrine 2017;55:360-365
4. Donath MY. Multiple benefits of targeting inflammation in the treatment of type 2 diabetes. Diabetologia 2016;59:679-682
5. Panova E, Jones G. Benefit-risk assessment of diacerein in the treatment of osteoarthritis. Drug Saf 2015;38:245-252
6. Pavelka K, Bruyère O, Cooper C, et al. Diacerein: Benefits, risks and place in the management of osteoarthritis. An opinion-based report from the ESCEO. Drugs Aging 2016;33:75-85
7. Martel-Pelletier J, Mineau F, Jolicoeur FC, CloutierJM, Pelletier JP. Invitroeffectsofdiacerhein and rhein on interleukin 1 and tumor necrosis factoralpha systems in human osteoarthritic synovium and chondrocytes. J Rheumatol 1998;25:753-762
8. Moore AR, Greenslade KJ, Alam CA, Willoughby DA. Effects of diacerhein on granuloma induced cartilage breakdown in the mouse. Osteoarthritis Cartilage 1998;6:19-23
9. Pelletier JP, Mineau F, Fernandes JC, Duval N, Martel-Pelletier J. Diacerhein and rhein reduce the interleukin 1beta stimulated inducible nitric oxide synthesis level and activity while stimulating cyclooxygenase-2 synthesis in human osteoarthritic chondrocytes. J Rheumatol 1998;25: 2417-2424
10. Tamura T, Ohmori K. Diacerein suppresses the increase in plasma nitric oxide in rat adjuvant-induced arthritis. Eur J Pharmacol 2001; 419:269-274
11. Malaguti C, Vilella CA, Vieira KP, Souza GH, Hyslop S, Zollner RdeL. Diacerhein downregulate proinflammatory cytokines expression and decrease the autoimmune diabetes frequency in nonobese diabetic (NOD) mice. Int Immunopharmacol 2008;8:782-791
12. Tobar N, Oliveira AG, Guadagnini D, et al. Diacerhein improves glucose tolerance and insulin sensitivity in mice on a high-fat diet. Endocrinology 2011;152:4080-4093
13. Du H, Shao J, Gu P, Lu B, Ye X, Liu Z. Improvement of glucose tolerance by rhein with restored early-phase insulin secretion in db/db mice. J Endocrinol Invest 2012;35:607-612
14. Liu J, Chen Z, Zhang Y, et al. Rhein protects pancreatic b-cells from dynamin-related protein-1-mediated mitochondrial fission and cell apoptosis under hyperglycemia. Diabetes 2013;62: 3927-3935
15. Jia ZH, Liu ZH, Zheng JM, Zeng CH, Li LS. Combined therapy of rhein and benazepril on the treatment of diabetic nephropathy in db/db mice. Exp Clin Endocrinol Diabetes 2007;115:571-576
16. Zheng JM, Zhu JM, Li LS, Liu ZH. Rhein reverses the diabetic phenotype of mesangial cells over-expressing the glucose transporter (GLUT1) by inhibiting the hexosamine pathway. Br J Pharmacol 2008;153:1456-1464
17. Sheng X, Wang M, Lu M, Xi B, Sheng H, Zang YQ. Rhein ameliorates fatty liver disease through negative energy balance, hepatic lipogenic regulation, and immunomodulation in diet-induced obese mice. Am J Physiol Endocrinol Metab 2011;300:E886-E893
18. Lin YJ, Hu G, Li KJ, Zhao YF, Wei J, Zhen YZ. The protection of rhein lysinate to liver in diabetic mice induced by high-fat diet and streptozotocin. Arch Pharm Res 2015;38:885-892
19. Ramos-Zavala MG, González-Ortiz M, Martínez-Abundis E, Robles-Cervantes JA, González-L ópez R, Santiago-Hernández NJ. Effect of diacerein on insulin secretion and metabolic control in drug-naive patients with type 2 diabetes: A randomized clinical trial. Diabetes Care 2011;34: 1591-1594
20. Ferreira MT, Leite NC, Cardoso CR, Salles GF. Correlates of aortic stiffness progression in patients with type 2 diabetes: Importance of glycemic control: The Rio de Janeiro Type 2 Diabetes Cohort Study. Diabetes Care 2015;38:897-904
21. Cardoso CR, Moran CB, Marinho FS, Ferreira MT, Salles GF. Increased aortic stiffness predicts future development and progression of peripheral neuropathy in patients with type 2 diabetes: The Rio de Janeiro Type 2 Diabetes Cohort Study. Diabetologia 2015;58:2161-2168
22. Cardoso CR, Leite NC, Salles GF. Prognostic importance of C-reactive protein in high cardiovascular risk patients with type 2 diabetes mellitus: The Rio de Janeiro Type 2 Diabetes Cohort Study. J Am Heart Assoc 2016;5:e004554
23. Levey AS, Stevens LA, Schmid CH, et al.; CKDEPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150:604-612
24. Goldfine AB, Fonseca V, Jablonski KA, et al.; Targeting Inflammation Using Salsalate in Type 2 Diabetes Study Team. Salicylate (salsalate) in patients with type 2 diabetes: A randomized trial. Ann Intern Med 2013;159:1-12
25. Gerstein HC, Thorpe KE, Taylor DW, Haynes RB. The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureasda randomized trial. Diabetes Res Clin Pract 2002;55:209-219
26. Pareek A, Chandurkar N, Thomas N, et al. Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: A double blind, randomized comparison with pioglitazone. Curr Med Res Opin 2014;30: 1257-1266
27. Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007;356:1517- 1526
28. Ridker PM, HowardCP, WalterV, et al.; CANTOS Pilot Investigative Group. Effects of interleukin-1b inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: A phase IIb randomized, placebo-controlled trial. Circulation 2012;126:2739-2748
29. Cavelti-Weder C, Babians-Brunner A, Keller C, et al. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care 2012;35:1654-1662
30. Gallwitz B, Rosenstock J, Rauch T, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: A randomised, double-blind, non-inferiority trial. Lancet 2012; 380:475-483
31. Spencer CM, Wilde MI. Diacerein. Drugs 1997;53:98-106; discussion 107-108
32. Louati K, Vidal C, Berenbaum F, Sellam J. Associationbetween diabetesmellitus andosteoarthritis: Systematic literature review and meta-analysis. RMD Open 2015;1:e000077
33. Marinho FS, Moram CB, Rodrigues PC, Franzoi AC, Salles GF, Cardoso CR. Profile of disabilities and their associated factors in patients with type 2 diabetes evaluated by the Canadian Occupational Performance Measure: The Rio De Janeiro Type 2 Diabetes Cohort Study. Disabil Rehabil 2016;38:2095-2101
34. EuropeanMedicines Agency.CMDh endorses recommendations to restrict the use of diacereincontaining medicines [Internet], 2014. Available from http://www.ema.europa.eu/docs/en-GB/ document-library/Referrals-document/Diacerein/ Position-provided-by-CMDh/WC500163532 .pdf. Accessed 26 May 2017
35. Lipska KJ, Krumholz HM. Is hemoglobin A1c the right outcome for studies of diabetes? JAMA 2017;317:1017-1018